D-allulose Agent for Brown Adipocyte Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for activating brown adipocytes are either ineffective or come with side effects, limiting their potential as a therapy for obesity and type 2 diabetes.
Innovation Solution
A brown adipocyte activating agent containing D-allulose, which promotes UCP-1 expression and beige adipocyte differentiation, offering a continuous and side-effect-free solution for enhancing energy consumption and fat burning.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods (catechins, capsaicin) are used to activate brown adipocytes, then some activation effect is achieved, but the effectiveness is insufficient and side effects occur
Solution Approach 1:
The patent changes the chemical parameter by using D-allulose (a rare sugar) instead of conventional activators like catechins or capsaicin. This parameter change results in superior activation effectiveness without the side effects associated with traditional methods, as D-allulose naturally activates brown adipocytes through a different biochemical pathway involving UCP-1 expression and beige adipocyte differentiation
Solution Approach 2:
The patent employs a natural sugar compound (D-allulose) that can be safely consumed continuously without accumulation of harmful effects. Unlike conventional drugs that may have severe side effects, D-allulose acts as a gentle, sustainable activator that can be taken long-term without causing harm, effectively replacing the need for potent but harmful conventional activators
2Duration of action of moving object
If conventional activators are used continuously, then activation effect is maintained, but side effects accumulate over time
Solution Approach 1:
The patent enables continuous activation of brown adipocytes through D-allulose supplementation. The rare sugar can be consumed daily without interruption, maintaining steady activation of UCP-1 expression and beige adipocyte differentiation throughout the treatment period, thereby achieving sustained weight management and metabolic improvement
Solution Approach 2:
D-allulose serves as a self-regulating activator that naturally activates brown adipocytes through its biochemical interaction with UCP-1 and adipocyte differentiation pathways. The body's own metabolic systems process D-allulose safely, eliminating the need for external monitoring or adjustment, and preventing accumulation of harmful effects during continuous use
Data Source
AI summary
To provide a brown and beige adipocyte activating agent and a brown and beige adipocyte activating food, each containing D-allulose as an active ingredient. Provided are a brown and beige adipocyte activating agent containing D-allulose as an active ingredient; a brown and beige adipocyte activating agent containing at least D-allulose and having a UCP-1 expression promoting action; a brown and beige adipocyte activating agent which enhances UCP-1 expression and thereby activates brown and beige adipocytes; an energy consumption promoting agent containing D-allulose as an active ingredient; an energy consumption promoting agent which activates brown and beige adipocytes and thereby promotes energy consumption; a UCP-1 expression enhancing agent containing D-allulose as an active ingredient; and a composition or food composition containing these agents.